LISA COLASURDO: Open Payments
NPI 1447246616 · INMAN, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$563 in 22 payments from 11 companies in 2025. Trend: 2023 $980 · 2024 $930 · 2025 $563
Food & beverage: $563
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $150 |
| Amgen Inc. | 4 | $135 |
| Abbott Laboratories | 3 | $63 |
| ABIOMED | 3 | $51 |
| Novartis Pharmaceuticals Corporation | 2 | $44 |
| Novo Nordisk Inc | 2 | $32 |
| Dexcom, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $19 |
| Merck Sharp & Dohme LLC | 1 | $16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
Products named: FARXIGA, EVENITY, FREESTYLE LIBRE 3, LEQVIO, Wegovy, Dexcom G6 Transmitter, Leqembi, VAXELIS.
Industry payments across SC — which companies pay providers there.
